CRISPR Therapeutics for protein modulation.

Moderna for targeted protein degradation therapies.

• NX-2127: An orally available IRAK4 degrader being developed for the treatment of hematologic malignancies.
• NX-5948: An orally available BTK degrader being developed for the treatment of B-cell malignancies.
• NX-0479: An orally available CBL-B inhibitor being developed to enhance T-cell activity in immuno-oncology.

Nurix Therapeutics (NRIX) is a biotechnology company primarily engaged in the discovery and development of novel small molecule medicines. As such, its major "customers" are strategic partners rather than individual patients or end-users.

The company sells primarily to other companies through strategic collaborations and partnerships for the research, development, and potential commercialization of its drug candidates and platform technology.

The major customer companies (partners) for Nurix Therapeutics are:

• Sanofi (SNY)
• Gilead Sciences (GILD)

null

Arthur T. Sands, M.D., Ph.D. President, Chief Executive Officer, and Board Director

Arthur T. Sands has served as the Chief Executive Officer and a member of Nurix's board of directors since September 2014. He co-founded Lexicon Pharmaceuticals, Inc. in 1995 and served as its President, Chief Executive Officer, and a director until July 2014. During his tenure at Lexicon, he pioneered the development of large-scale gene knockout technology for drug discovery and guided the company's growth from a research-stage entity to a drug development company, generating over $450 million in revenue through various alliances. Dr. Sands also led Nurix through its successful IPO in 2020. He is an adjunct professor in the Department of Human and Molecular Genetics at Baylor College of Medicine.

Hans van Houte Chief Financial Officer

Hans van Houte has served as Chief Financial Officer of Nurix since June 2020 and has led the company's finance team since 2015. He has been instrumental in instituting rigorous financial controls for public company reporting and in spearheading capital raises exceeding $500 million. Before joining Nurix, Mr. van Houte held senior finance positions at Vertex Pharmaceuticals, where he contributed to scaling the financial and accounting organization after its IPO. He also served as Vice President of Finance and Operations at Trubion Pharmaceuticals during its IPO and was a managing partner at Bionation LLC.

Gwenn M. Hansen, Ph.D. Chief Scientific Officer

Gwenn M. Hansen has served as Chief Scientific Officer of Nurix since June 2020. In this role, she leads the company's discovery efforts, including the establishment of its DNA-encoded library technology and the advancement of multiple lead degrader programs. Dr. Hansen joined Nurix in 2015, and prior to that, she was an Associate Professor at Baylor College of Medicine's Center for Drug Discovery and held senior discovery roles at Lexicon Pharmaceuticals.

Christine Ring, Ph.D., J.D. Chief Legal Officer and Chief Compliance Officer

Christine Ring has served as Chief Legal Officer and Chief Compliance Officer of Nurix since October 2023, as Secretary since March 2020, and as General Counsel since September 2019. Before joining Nurix, Dr. Ring held multiple positions where she assisted companies in protecting intellectual property, engaging in licensing transactions, raising capital, and transitioning from private to public entities. Her previous roles include Senior Vice President, Legal at Dermira, Inc., and Senior Vice President of Technology, Strategy and Licensing at Amyris, Inc.

Jason Kantor, Ph.D. Chief Business Officer

Jason Kantor has served as Chief Business Officer of Nurix since October 2023. He has also held senior finance and business strategy roles since joining the company in July 2020. Previously, Dr. Kantor was a Senior Biopharma Analyst at Artisan Partners, where he covered industry trends for both large and small-cap biotech and pharmaceutical companies globally. He also served as Board President at Biotech Partners. From 2021, he was the Head of Research and Development, overseeing the translational development of targeted degrader and ligase inhibitor programs.

Nurix Therapeutics' main pipeline products target several significant addressable markets:

• NX-5948 (bexobrutideg), a Bruton's tyrosine kinase (BTK) degrader, is in development for Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL), including Waldenstrom Macroglobulinemia (WM) and Diffuse Large B-cell Lymphoma (DLBCL). It is also being explored for autoimmune diseases like warm autoimmune hemolytic anemia (wAIHA).

  • For Chronic Lymphocytic Leukemia, the global market is estimated to reach $24.3 billion by 2033. The global therapeutics market for CLL was USD 5.42 billion in 2025 and is forecast to achieve USD 7.46 billion by 2030. Another estimate projects the global market to reach US$ 17.17 billion by 2029. The global treatment market for CLL was estimated at USD 5.75 billion in 2024 and is projected to grow to USD 10.16 billion by 2035.
  • For Relapsed or Refractory Diffuse Large B-cell Lymphoma (a type of NHL), the global market is estimated to be valued at USD 1,610.0 million in 2025 and is expected to reach USD 2,161.8 million by 2032. North America is projected to hold a dominant position in this market. The DLBCL market size was USD 4.7 billion in the leading markets (US, EU4, UK, and Japan) in 2024 and is expected to surpass USD 11.5 billion by 2034 in the United States.

• NX-1607, an inhibitor of CBL-B, is being developed for immuno-oncology indications, including advanced malignancies, solid tumor types, and lymphoma.

  • The addressable market for advanced malignancies and lymphoma would overlap with the NHL market mentioned above.

• NX-2127, an orally available BTK degrader, is designed for the treatment of relapsed or refractory B-cell malignancies.

  • The addressable market for relapsed or refractory B-cell malignancies includes conditions like those covered under NHL and CLL.

• GS-6791 (NX-0479), an IRAK4 degrader, targets chronic inflammatory diseases such as rheumatoid arthritis and atopic dermatitis. The STAT6 degrader program, in collaboration with Sanofi, also targets type 2 inflammation and allergic conditions like atopic dermatitis or asthma. While specific market sizes for rheumatoid arthritis or atopic dermatitis were not extensively detailed for Nurix, the broader market for autoimmune and inflammatory diseases is substantial, as seen with lupus.

  • For Lupus (Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus), the global lupus drugs market (systemic lupus erythematosus and lupus nephritis) is estimated to reach $5.1 billion by 2033. The global systemic lupus erythematosus market size was valued at USD 2.60 billion in 2023 and is projected to reach USD 4.26 billion by 2030, with North America dominating the market. The global lupus market size was USD 3.97 billion in 2024 and is projected to reach USD 11.70 billion by 2035, with the North America lupus market accounting for USD 3.3 billion in 2022. The global cutaneous lupus erythematosus market size was valued at USD 2.93 billion in 2024 and is projected to reach USD 7.90 billion by 2032. The global systemic lupus erythematosus market size was estimated to be USD 2.83 billion in 2023 and is expected to reach USD 6.19 billion by 2034.

Nurix Therapeutics (NRIX) is anticipated to drive future revenue growth over the next 2-3 years through the advancement of its clinical pipeline, the achievement of milestones from strategic collaborations, and the expansion into new therapeutic areas, particularly autoimmune diseases.

1. Advancement and Potential Commercialization of Lead Clinical Candidates: A primary driver of future revenue for Nurix is the progression and potential commercialization of its lead proprietary drug candidates. Notably, bexobrutideg (NX-5948), an investigational Bruton's tyrosine kinase (BTK) degrader, is expected to initiate pivotal trials in Chronic Lymphocytic Leukemia (CLL) in 2025. Successful clinical development and subsequent regulatory approval of NX-5948 in CLL and other B-cell malignancies would lead to significant product revenue. Additionally, other pipeline candidates such as NX-1607, an oral CBL-B inhibitor, which recently showcased promising Phase 1 data demonstrating immune activation, and NX-2127, currently in a Phase 1a/b oncology trial, contribute to future revenue potential as they advance through development.
2. Achievement of Milestones and Potential Royalties from Strategic Partnerships: Nurix maintains active strategic collaborations with major pharmaceutical companies including Gilead Sciences, Sanofi, and Pfizer. These partnerships are a crucial source of current and future revenue through research collaboration milestones and potential royalties on future product sales. The company anticipates continuing to achieve substantial research collaboration milestones throughout the terms of these agreements. For example, Q2 2025 revenue included significant license fees from Sanofi and a clinical milestone payment from Gilead.
3. Pipeline Expansion into Autoimmune Diseases: Nurix is strategically expanding its therapeutic focus beyond oncology into autoimmune and inflammatory diseases. This expansion is expected to open new market opportunities and diversify revenue streams. A key asset in this area is GS-6791 (NX-0479), an IRAK4 degrader developed in collaboration with Gilead, which received FDA clearance for an Investigational New Drug (IND) application. Preclinical data for GS-6791 has demonstrated potent IRAK4 degradation and promising effects in models of dermatitis, supporting its continued development in autoimmune conditions. The company anticipates filing an IND for another autoimmune disease treatment in 2025.

Share Issuance

• In October 2025, Nurix Therapeutics completed an underwritten registered offering of 24,485,799 shares of common stock at $10.21 per share, generating gross proceeds of $250.0 million.
• In April 2024, Nurix Therapeutics closed an underwritten public offering of 11,916,667 shares of its common stock at $15.00 per share, which included shares issued upon the exercise of underwriters' option to purchase additional shares. The net proceeds from this offering were approximately $188.6 million.
• In July 2022, Nurix Therapeutics completed two registered direct offerings of pre-funded warrants to purchase common stock, resulting in $95.0 million in gross proceeds. One of these offerings was for approximately $40 million for 2,869,440 shares of common stock.

Inbound Investments

• In September 2023, Nurix entered into a strategic collaboration with Seagen (now Pfizer) to develop Degrader-Antibody Conjugates (DACs), receiving an upfront payment of $60 million with potential for approximately $3.4 billion in milestone payments.
• For fiscal year 2023, Nurix achieved $100 million in non-dilutive capital from partners, including upfront and milestone payments such as a $20.0 million license option exercise payment from Gilead.
• Collaborations with Sanofi and Gilead initiated around March 2020 provided Nurix with $100 million in upfront payments and potential for over $4.5 billion in milestones.

Capital Expenditures

• Nurix Therapeutics indicated in July 2022 that proceeds from a $40 million offering would be used, in part, to fund capital expenditures.
• In the third fiscal quarter of 2023, Nurix experienced an increase in facility and other costs, primarily due to additional investments in information technology and lease-related expenses.
• Research and development expenses, which can include capital investments in facilities and equipment for research, increased to $189.1 million in fiscal year 2023 from $184.5 million in fiscal year 2022, primarily driven by higher personnel costs and clinical trial activities.